Stay updated with breaking news from Zai Labs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The plan relegates the CSRC to the back seat in the auditing dispute between the US and China, from the role it has held since 2016 as the collector and gatekeeper of China’s audit working papers.
ARGX earnings call for the period ending September 30, 2021.
Entasis Therapeutics, the former anti-infectives unit of AstraZeneca, has positive Phase 3 data for its lead program, an antibiotic that could address drug-resistant strains of Acinetobacter baumannii that contribute to hospital-acquired infections. The biotech plans to seek FDA approval in 2022.
Search jobs RubrYc Therapeutics Announces a Research Collaboration and License Option Agreement With Zai Labs SAN CARLOS, Calif.--(BUSINESS WIRE)--RubrYc Therapeutics, Inc., a pre-clinical biotherapeutics company developing epitope selective therapies, today announced that it has entered into a research collaboration and license option agreement with Zai Labs, Inc. for the use of RubrYc’s Meso-scale Engineered Molecules (MEMs) platform, to identify monoclonal antibodies with enhanced biological function for an undisclosed oncology target. Under the terms of the agre...
Search Home / Profile / Linden Thomson: It’s no surprise first vaccines came from biotech rather than large-cap pharma Linden Thomson: It’s no surprise first vaccines came from biotech rather than large-cap pharma Axa Framlington Biotech fund manager on vaccine makers thriving even after Covid In November, markets received the first hopeful phase-III trial data from a Covid-19 vaccine candidate. Pfizer is the name most closely attached to the vaccine rolled out in the UK just before Christmas, but Axa Investment Managers biotechnology fund manager Linden Thomson says ...